Sentiment Trading

Oncoinvent ASA and BerGenBio ASA have announced a strategic merger, combining their expertise in radiopharmaceutical cancer therapies to accelerate innovation and improve treatment options for cancer patients.

Oncoinvent ASA’s Phase 1 ovarian cancer trial shows promising results, with no new recurrences among 10 patients over an 18-month follow-up period, bolstering the potential of its radiopharmaceutical treatment Radspherin.